| Literature DB >> 33168067 |
Caroline French1, Hilary Pinnock2, Gordon Forbes3, Imogen Skene4, Stephanie J C Taylor5.
Abstract
BACKGROUND: Process evaluations are increasingly conducted within pragmatic randomised controlled trials (RCTs) of health services interventions and provide vital information to enhance understanding of RCT findings. However, issues pertaining to process evaluation in this specific context have been little discussed. We aimed to describe the frequency, characteristics, labelling, value, practical conduct issues, and accessibility of published process evaluations within pragmatic RCTs in health services research.Entities:
Keywords: Health services research; Pragmatic randomised controlled trials; Process evaluation
Mesh:
Year: 2020 PMID: 33168067 PMCID: PMC7650157 DOI: 10.1186/s13063-020-04762-9
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Fig. 1Method overview
MRC process evaluation components (adapted from [4], with definitions in italics where provided in original)
Data outcomes for process evaluation publications
| Review objective | Type of data | Outcomes |
|---|---|---|
| Quantitative | • Use of label ‘process evaluation’ anywhere in the set of papers for the trial • Use of keyword ‘process evaluation’ for indexing | |
| Quantitative | • Process evaluation components (mapped from aims and qualitative findings) • Whether processes related to the intervention or trial • Methodology • Data collection method | |
| Qualitative | • Practical issues relating to designing or operationalising the process evaluation | |
| Qualitative | • Reported rationales for undertaking, or implications of the process evaluation | |
| Quantitative | • Publishing journal • Time to publication from trial results paper • Search method required to locate paper • Mention of the process evaluation in trial results paper • Where in paper the trial first named or referenced • Inclusion in trial registry |
Fig. 2Adapted PRISMA flow diagram [18]. The asterisk indicates searches conducted in order stated and each record included only under search method first found
Characteristics of the index sample of pragmatic RCTs
| Individual | 25 | Usual care | 15 |
| Cluster | 6 | Other intervention(s) | 10 |
| Stepped-wedge control period | 2 | ||
| Comparing two settings | 1 | ||
| 2-arm | 22 | Comparing two deliverers | 1 |
| Non-inferiority (2-arm) | 4 | No intervention | 1 |
| 3-arm | 3 | Sham clinical procedure | 1 |
| Crossover | 1 | ||
| Stepped-wedge | 1 | ||
| British Medical Journal | 7 | ||
| Lancet | 7 | ||
| No evidence of effect | 15 | JAMA | 5 |
| Evidence of effect | 11 | Canadian Medical Association Journal | 2 |
| Non-inferiority trial | 4 | JAMA Pediatrics | 2 |
| Unclear | 1 | Critical Care Medicine | 1 |
| Gut | 1 | ||
| JAMA Internal Medicine | 1 | ||
| Public | 25 | JAMA Psychiatry | 1 |
| Multiple funders | 3 | Journal of Allergy and Clinical Immunology | 1 |
| Charity | 1 | New England Journal of Medicine | 1 |
| Independent Organisation | 1 | Nursing Research | 1 |
| Not reported | 1 | The American Journal of Psychiatry | 1 |
| Pharmacological treatment strategy | 9 | UK | 12 |
| Clinical procedure | 4 | USA | 8 |
| Therapy intervention | 4 | Australia | 3 |
| Clinical treatment strategy | 3 | Netherlands | 2 |
| Model of care provision | 3 | Brazil | 1 |
| Reminder system | 3 | Canada | 1 |
| Health promotion | 3 | France | 1 |
| Medical device | 2 | France, Belgium and Switzerland | 1 |
| Hong Kong | 1 | ||
| North Americaa | 1 | ||
aCountries not specified in original article
Included process evaluation studies
| Reference(s) | Description of process evaluation | Methodology and data collection methods | Intervention or trial processes | Process evaluation components | Labelled as process evaluation |
|---|---|---|---|---|---|
| Ball 2018 [ | Investigated the effect of mild cognitive impairment in participants on intervention outcome | Quantitative Trial dataset | Intervention | Contextual moderators | No |
| Clark 2015 [ | Explored patient perceptions of the acceptability of intervention in both groups, and motivations for agreeing or refusing to participate in the trial | Qualitative Interviews | Intervention and trial | Participant responses Reach Contextual moderators Unintended consequences Causal mechanisms in context | No |
| Grubbs 2015 [ | Investigated which factors predicted patient uptake of an element of the intervention found to mediate the primary outcome | Quantitative Medical record review | Intervention | Contextual moderators | No |
| Handoll 2016 [ | Described how the intended fracture population was practically achieved in pragmatic RCT, including results of formal independent assessment and classification of trial fractures | Quantitative Detailed author description Trial dataset | Intervention and trial | Reach | No |
| Handoll 2015 [ | |||||
| Handoll 2014 [ | Described processes undertaken to ensure usual care received by both groups in trial was good quality and comparable, including results of methods described | Quantitative Detailed author description Deliverer self-report | Intervention and trial | How delivery is achieved Fidelity | No |
| Handoll 2015 [ | |||||
| Hall 2017 [ | Investigated mediators of intervention outcome | Quantitative Trial dataset | Intervention | Mediators | No |
| Hill 2016 [ | Explored perceptions of ward staff about how intervention contributed to outcome, and experience of intervention being delivered on their ward | Qualitative Focus groups | Intervention | How delivery is achieved Participant responses Contextual moderators Causal mechanisms in context Contextual factors shaping intervention theory | No |
| Hill 2016 [ | Explored patient experiences of intervention and perceived barriers to engagement | Qualitative Semi-structured questionnaires | Intervention | Participant responses Causal mechanisms in context Contextual factors shaping intervention theory | Yes |
| Hill 2015 [ | Explored perceptions of intervention deliverers of delivering intervention and how the intervention worked | Qualitative Focus groups, interview, field notes, intervention notes | Intervention | How delivery is achieved Contextual factors shaping intervention theory Participant responses Causal mechanisms in context | Yes |
| Keding 2019 [ | Explored how patient and surgeon treatment preferences impacted recruitment, trial conduct, and patient outcomes | Quantitative Trial dataset | Intervention and trial | Reach Participant responses Contextual moderators | No |
| Handoll 2015 [ | |||||
| Knowles 2015 [ | Explored patient experiences of the intervention, including acceptability, ease of use, barriers to engagement, content, accessibility, and support. Also explored healthcare professional perceptions of feasibility and which patients’ intervention most suited to. | Qualitative Interviews | Intervention | Participant responses How delivery is achieved Reach Causal mechanisms in context Contextual moderators Unintended consequences Contextual factors shaping intervention theory | Yes |
| Littlewood 2015 [ | |||||
| Nichols 2017 [ | Explored experiences of patients about intervention, with focus on patient adherence, and how changed over time | Qualitative Interviews (longitudinal) | Intervention | Participant responses Causal mechanisms in context Contextual moderators How delivery is achieved | No |
| Williams 2015 [ | |||||
| Novak 2015 [ | Investigated whether and how trial sites supplied thawed plasma in a timely manner | Quantitative Detailed author description Observation, reports from sites | Intervention and trial | Fidelity How delivery is achieved | No |
| Sands 2016 [ | Explored how the flexible complex intervention was delivered in real-world complex settings | Qualitative Trial dataset | Intervention | How delivery is achieved Adaptations Contextual moderators Participant responses Unintended consequences Contextual factors shaping intervention theory Fidelity | No |
| Saville 2016 [ | Explored preferences and experiences of intervention deliverers about various aspects of intervention | Quantitative Questionnaire | Intervention | How delivery is achieved | No |
| Tjia 2017 [ | Investigated patients’ perceptions of benefits and drawbacks of intervention | Quantitative Questionnaire | Intervention | Participant responses | No |
| Vennik 2019 [ | Explored views and experiences of parents and practice nurses of intervention and usual care | Qualitative Interviews | Intervention | Participant responses How delivery is achieved Contextual factors shaping intervention theory Causal mechanisms in context Unintended consequences | No |
| Williamson 2016 [ |
Fig. 3MRC process evaluation components reported in the trial results papers and process evaluations
Fig. 4Reported barriers and facilitators
Fig. 5Synthesis of reported values of process evaluation studies
Reported value subthemes
| Subtheme | Number of process evaluations reporting this value ( | Examples of reported values in subtheme |
|---|---|---|
| 16 | • Informing future trial design [ • Improving future design of similar interventions [ | |
| 15 | • Providing evidence of feasibility [ • Highlighting potential disadvantages of intervention to facilitate consent discussions with patients [ | |
| 10 | • Adding stronger monitoring protocols to promote adherence [ • Recommendation to research effectiveness over time [ | |
| 8 | • Reasons for non-positive results [ • Reasons for positive results [ | |
| 7 | • Concern about the effect of cognitive impairment on effectiveness [ • Concern about participant adherence [ | |
| 6 | • Participant and deliverer experiences and perceptions [ • Nuance and context [ | |
| 6 | • Investigating threats to internal validity [ • Accurately defining trial population [ | |
| 4 | • Understanding what was delivered in a flexible intervention [ • Mechanisms of impact [ | |
| 2 | • Exploring findings of subgroup analysis [ | |
| 2 | • Evaluating whether intended pragmatic trial population achieved [ | |
| 1 | • Highlighting gaps in current care provision [ | |
| 1 | • Adhere to reporting standards for pragmatic and non-pharmacological trials [ | |
| 1 | • Following MRC recommendations [ |
Summary of recommendations
• Consider the identified potential values of process evaluation within pragmatic RCTs and how these may be realised and articulated to stakeholders • We encourage debate about the meaning of the label ‘process evaluation’ and how it may be more consistently applied | |
| • Consider the identified barriers and facilitators and how to address these when conducting process evaluations in health services settings | |
• Ensure process evaluation publications are included in the trial registry entry • Ensure process evaluations are mentioned in journal articles reporting the parent trial, and consider adding this item to relevant CONSORT checklists • Ensure process evaluation publications name or refer to the parent trial in the title or abstract • Publish strategies for conducting successful process evaluations and addressing challenges in health services settings, such as to recruiting process evaluation participants and collecting data |